Source: Virtual Congress 2021 – All about pulmonary arterial hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
E. Swietlik (Cambridge, United Kingdom), D. Greene (Cambridge, United Kingdom), K. Auckland (Cambridge, United Kingdom), T. Tilly (Cambridge, United Kingdom), J. Martin (Cambridge, United Kingdom), N. Translational Research (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), S. Gräf (Cambridge, United Kingdom). Late Breaking Abstract - Convergence of clinical and computational phenotypes for rare variant association study (RVAS) in pulmonary arterial hypertension. 149

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study) Source: International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities Year: 2019 New rare variant associations with distinct phenotypes in patients with pulmonary arterial hypertension revealed with Bayesian inference. Source: Virtual Congress 2020 – Genetics and genomics of pulmonary arterial hypertension Year: 2020 Late Breaking Abstract - Molecular mechanisms involved in early stage of pulmonary hypertension: experimental study Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients Source: Eur Respir J 2012; 39: 597-603 Year: 2012 Late Breaking Abstract - Inflammation and metabolic syndrome exacerbate pulmonary hypertension associated with left heart disease. Source: International Congress 2019 – Pulmonary hypertension: new therapeutic pathways and modalities Year: 2019 Late Breaking Abstract: Pulmonary hypertension (PH) in patients with idiopathic pulmonary fibrosis (IPF) in early course of disease – A prospective evaluation with right heart catheterization (RHC) in the ARTEMIS-IPF study Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010 A new molecular genetic diagnostic approach for pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Is pulmonary arterial hypertension associated with interferon-ß therapy for multiple sclerosis reversible? A case study to explore the complexity Source: ERJ Open Res, 6 (1) 00328-2019; 10.1183/23120541.00328-2019 Year: 2020 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Stress-Doppler-Echocardiography for early detection of systemic sclerosis associated pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: role of the pre-capillary component Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Characteristics of a stable and satisfactory condition in long term survivors of pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Correspondence regarding “T-box protein 4 mutation causing pulmonary arterial hypertension and lung disease”: a single-centre case series Source: Eur Respir J, 55 (5) 1902272; 10.1183/13993003.02272-2019 Year: 2020 Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns Source: Eur Respir J, 53 (3) 1900135; 10.1183/13993003.00135-2019 Year: 2019 ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre Source: Eur Respir J 2012; 39: 945-955 Year: 2012 Accelerated variant of idiopathic pulmonary fibrosis: clinical and molecular behaviour Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007 Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013